VolitionRx and Active Motif enter into Distribution Agreement for Volition's Research Use Only ELISA Kits.
NAMUR, Belgium, Sept. 26, 2013 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today entered into an agreement with Active Motif, a leading provider of kits and reagents to enable epigenetics research. The terms of the agreement will see Active Motif become the co-exclusive (with VolitionRx) distributor of the NuQ® product line to scientists and researchers in Europe, the United States and Japan.
The NuQ® range of products is based on the Nucleosomics® platform, which identifies and quantifies nucleosome structural features such as histone modifications and variations, DNA methylation patterns and nucleosome-protein adducts. The initial range comprises 15 immunoassays across four families, each of which captures intact nucleosomes and detects a specific feature. The kits are currently available to a wide range of researchers wishing to study epigenetics. This type of research is applicable to many disease areas in addition to diverse biological fields such as apoptosis, embryology and stem cell research.
Thomas Bygott, VolitionRx's Director of Sales & Marketing, says of the agreement, "This partnership goes beyond just the distribution of our kits - Active Motif is a technology partner whose expertise in antibody development has assisted us in developing this unique line of products. In addition they have an extensive network of highly specialist sales teams in the US, Japan and across Europe that can help scientists choose the most suitable experiments for their needs, as well as a wide range of distributors across the world. Active Motif is committed to being a producer of quality antibodies and providing a high level of service to the scientists who use its products, making it an ideal partner for VolitionRx."
Gary Shiels Ph.D., Director of Global Marketing at Active Motif, also commented, "The NuQ® ELISA kits that VolitionRx has developed are a perfect complement to our existing range of research tools for epigenetic analysis. The study of intact nucleosomes opens up a whole new set of options for the experiments that scientists can perform, moving closer to the natural environment in which epigenetic modifications and variations occur."
"We believe that Active Motif is the ideal partner to assist us in targeting researchers working in additional research areas outside of cancer, where the identification of nucleosomes is also useful," says Cameron Reynolds, the CEO of Volition. "We aim to use the early revenue from the unregulated Research Only kits to assist with the funding of our previously announced on-going clinical trials."
VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present. VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.
Visit Volition's website (www.volitionrx.com) or connect with them via Twitter, LinkedIn or Facebook.
About Active Motif
Active Motif, Inc. is dedicated to developing, manufacturing and delivering epigenetics-based research tools to analyse nuclear function. Its customers include life scientists from academic and government institutions; biotechnology and pharmaceutical companies; hospitals and reference laboratories. Active Motif operates globally through its corporate headquarters in Carlsbad, California regional headquarters in Belgium and Japan and a worldwide network of sales and support offices. Active Motif applies a multi-disciplinary approach to create new and modify existing technologies to meet the current and future needs of life science researchers.
Forward-Looking Statements: Statements in this press release may be "forward-looking statements". Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.
SOURCE VolitionRx Limited